• Altria pays a quarterly dividend of $1.06 per share, producing a forward yield of 6.42% near $66.09.
• MO dividends have a long growth record, but a payout ratio near 77% limits flexibility if profits decline.
• Altria shares trade above one fair-value estimate, making a lower entry price more appealing for new income investors.

Altria remains built for income, though valuation and slow growth demand patience.

Altria Group (NYSE: MO) offers dividend investors a quarterly payment of $1.06 per share, or $4.24 annually, translating to a forward yield of 6.42% at a share price near $66.09. The income stream is supported by a history of shareholder returns, with Altria raising its dividend 60 dividend increases over 56 years.

The central question for MO dividend investors is whether the current income adequately compensates for declining cigarette volumes, regulatory risks and modest earnings growth.

High Yield With Modest Growth

The dividend remains the central attraction for long-term holders.

MO’s current quarterly dividend was unchanged from the prior payout, while its dividend-growth record remains steady rather than rapid. The annualized dividend has grown roughly 3.9% over one year, 4.1% over three years and 4.3% over five years.

That produces a respectable income-growth profile alongside the current yield. MO’s Chowder score, which combines yield and five-year dividend-growth rate, is about 10.7.

However, its earnings payout ratio stands near 77%, leaving less room for dividend increases if profits weaken. Investors should expect low- to mid-single-digit MO dividend growth rather than the rapid increases seen in earlier decades.

Smoke-Free Progress Offers a Catalyst

Oral nicotine products could help offset the mature cigarette franchise.

Altria’s core cigarette business remains under pressure, with second-quarter revenue flat at $6.1 billion while diluted EPS fell 3%. Marlboro still represents more than 90% of sales, leaving the company exposed to a declining combustible-tobacco market.

The expansion of Altria’s on! nicotine-pouch portfolio provides a potential growth outlet beyond cigarettes. Additional FDA marketing authorizations improve its position in reduced-risk nicotine, though competitive, regulatory and consumer-adoption risks remain.

Management is also supporting per-share results through buybacks. Altria repurchased 5.3 million shares for $335 million during the first half of 2026, with remaining authorization available through year-end.

Valuation Leaves Less Margin of Safety

The shares are no longer priced like a deep-value tobacco investment.

At roughly $66, MO trades at 13.9 times trailing earnings, slightly above its five-year median multiple. One valuation estimate places fair value at $57.64, implying shares trade at a 14.7% premium.

The stock remains above its 52-week low of $54.70, although below its $77.06 high. A pullback toward the low-$60s, or below, would improve the entry yield and downside cushion.

Existing shareholders can reasonably hold MO for its 6%-plus income, buybacks and defensive cash generation. New investors may prefer to build a position gradually or wait for a higher yield while monitoring cigarette volumes, adjusted EPS guidance, free-cash-flow coverage, oral-nicotine execution and any change in the $1.06 quarterly dividend.